Mer­ck goes in deep­er with Keytru­da/Lyn­parza com­bo; PureTech un­veils stem cell ther­a­py start­up

→ Mer­ck is open­ing up a new wing of its Keytru­da pipeline, de­vot­ing it to a slate of new Phase III com­bi­na­tion stud­ies with Lyn­parza in treat­ing prostate can­cer. Re­searchers spot­ted an­ti-tu­mor ac­tiv­i­ty in 3 co­horts, send­ing them the sig­nal they were look­ing for to pile on piv­otal stud­ies in search of a new mar­ket. “These promis­ing da­ta pre­sent­ed at AS­CO GU cou­pled with the sig­nif­i­cant un­met med­ical need in pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer, pro­pelled us to ini­ti­ate three new Phase 3 tri­als to fur­ther eval­u­ate these KEYTRU­DA com­bi­na­tion reg­i­mens,” not­ed Mer­ck’s Roy Baynes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.